These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

815 related items for PubMed ID: 28008158

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
    Mills MN, Yang GQ, Oliver DE, Liveringhouse CL, Ahmed KA, Orman AG, Laronga C, Hoover SJ, Khakpour N, Costa RLB, Diaz R.
    Eur J Cancer; 2018 Jul; 98():48-58. PubMed ID: 29870876
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database.
    Wang XX, Jiang YZ, Liu XY, Li JJ, Song CG, Shao ZM.
    Oncotarget; 2016 Apr 19; 7(16):22665-73. PubMed ID: 27009810
    [Abstract] [Full Text] [Related]

  • 6. Clinicopathological characteristics and survival outcomes in breast carcinosarcoma: A SEER population-based study.
    Lin S, Liu C, Tao Z, Zhang J, Hu X.
    Breast; 2020 Feb 19; 49():157-164. PubMed ID: 31812891
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.
    Zhang J, Wang Y, Yin Q, Zhang W, Zhang T, Niu Y.
    Int J Clin Exp Pathol; 2013 Feb 19; 6(7):1380-91. PubMed ID: 23826420
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
    Chen HL, Ding A.
    Breast; 2015 Dec 19; 24(6):723-31. PubMed ID: 26392199
    [Abstract] [Full Text] [Related]

  • 15. The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database.
    Chen QX, Wang XX, Lin PY, Zhang J, Li JJ, Song CG, Shao ZM.
    Oncotarget; 2017 Jan 17; 8(3):4773-4780. PubMed ID: 27999201
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
    Di Saverio S, Gutierrez J, Avisar E.
    Breast Cancer Res Treat; 2008 Oct 17; 111(3):541-7. PubMed ID: 18026874
    [Abstract] [Full Text] [Related]

  • 18. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
    Wu W, Wu M, Peng G, Shi D, Zhang J.
    Cancer Med; 2019 Dec 17; 8(18):7523-7531. PubMed ID: 31642210
    [Abstract] [Full Text] [Related]

  • 19. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC, Rastogi P, Geyer CE, Miller LD, Thomas A.
    Oncologist; 2018 Apr 17; 23(4):481-488. PubMed ID: 29330212
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.